カテゴリー： QYResearch, 世界

ベータラクタムおよびベータラクタマーゼ阻害剤の世界市場：規模・現状・予測2019-2025

【英語タイトル】Global Beta-lactam and Beta-lactamase Inhibitors Market Size, Status and Forecast 2019-2025

QYResearchが出版した調査資料（DATA909X18221）・商品コード：DATA909X18221
・発行会社（調査会社）：QYResearch
・発行日：2019年11月25日（※2024年版があります。お問い合わせください）
・ページ数：97
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品・ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,900 ⇒換算￥577,200見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD5,850 ⇒換算￥865,800見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD7,800 ⇒換算￥1,154,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
※当調査レポートでは、ベータラクタムおよびベータラクタマーゼ阻害剤の世界市場について調査・分析し、ベータラクタムおよびベータラクタマーゼ阻害剤の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（ペニシリン、セファロスポリン、カルバペネム、モノバクタム、コンビネーション）、用途別（経口、静脈内、その他）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。


・レポートの概要
・世界のベータラクタムおよびベータラクタマーゼ阻害剤市場動向
・主要企業別マーケットシェア
・ベータラクタムおよびベータラクタマーゼ阻害剤の種類別市場規模2014-2019
（ペニシリン、セファロスポリン、カルバペネム、モノバクタム、コンビネーション）
・ベータラクタムおよびベータラクタマーゼ阻害剤の用途別市場規模2014-2019
（経口、静脈内、その他）
・ベータラクタムおよびベータラクタマーゼ阻害剤の北米市場：主要企業・種類別/用途別市場規模
・ベータラクタムおよびベータラクタマーゼ阻害剤のヨーロッパ市場：主要企業・種類別/用途別市場規模
・ベータラクタムおよびベータラクタマーゼ阻害剤の中国市場：主要企業・種類別/用途別市場規模
・ベータラクタムおよびベータラクタマーゼ阻害剤の日本国内市場：主要企業・種類別/用途別市場規模
・ベータラクタムおよびベータラクタマーゼ阻害剤の東南アジア市場：主要企業・種類別/用途別市場規模
・ベータラクタムおよびベータラクタマーゼ阻害剤のインド市場：主要企業・種類別/用途別市場規模
・ベータラクタムおよびベータラクタマーゼ阻害剤の中南米市場：主要企業・種類別/用途別市場規模
・主要企業のプロフィール
（Abbott Laboratories、Allergan Plc.、F. Hoffmann-La Roche Ltd.、GlaxoSmithKline plc、Merck & Co. Inc.、Mylan N.V.、Novartis International AG (Sandoz)、Pfizer Inc.、Sanofi、Teva Pharmaceutical Industries Ltd）
・ベータラクタムおよびベータラクタマーゼ阻害剤の市場規模予測2019-2025
（種類別、用途別、地域別市場予測）
・アナリストの観点・結論
...
【レポートの概要】

Beta-lactam antibiotics are a class of antibiotics consisting of all antibiotic agents that contain a beta-lactam ring in their molecular structures. This includes penicillin derivatives, cephalosporins, monobactams, and carbapenems. These are the antimicrobial substances or compounds that fight against bacterial infections and sometimes with protozoan infections. In addition, these medications either kill the bacteria directly or stop the bacteria from growing. However, these drugs are easily available at over-the-counter (OTC) and one can buy these without a prescription in most of the countries, which leads to overuse or misuse. Thereby, bacterial resistance is developing the beta-lactam antibiotics.
In 2018, the global Beta-lactam and Beta-lactamase Inhibitors market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Beta-lactam and Beta-lactamase Inhibitors status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Beta-lactam and Beta-lactamase Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
Abbott Laboratories
Allergan Plc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Merck & Co. Inc.
Mylan N.V.
Novartis International AG (Sandoz)
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd

Market segment by Type, the product can be split into
Penicillin
Cephalosporin
Carbapenem
Monobactam
Combination

Market segment by Application, split into
Oral
Intravenous
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Beta-lactam and Beta-lactamase Inhibitors status, future forecast, growth opportunity, key market and key players.
To present the Beta-lactam and Beta-lactamase Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Beta-lactam and Beta-lactamase Inhibitors are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate by Type (2014-2025)
1.4.2 Penicillin
1.4.3 Cephalosporin
1.4.4 Carbapenem
1.4.5 Monobactam
1.4.6 Combination
1.5 Market by Application
1.5.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Application (2019-2025)
1.5.2 Oral
1.5.3 Intravenous
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Beta-lactam and Beta-lactamase Inhibitors Market Size
2.2 Beta-lactam and Beta-lactamase Inhibitors Growth Trends by Regions
2.2.1 Beta-lactam and Beta-lactamase Inhibitors Market Size by Regions (2019-2025)
2.2.2 Beta-lactam and Beta-lactamase Inhibitors Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players
3.1 Beta-lactam and Beta-lactamase Inhibitors Market Size by by Players
3.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by by Players (2014-2019)
3.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by by Players (2014-2019)
3.1.3 Global Beta-lactam and Beta-lactamase Inhibitors Market Concentration Ratio (CR5 and HHI)
3.2 Beta-lactam and Beta-lactamase Inhibitors Key Players Head office and Area Served
3.3 Key Players Beta-lactam and Beta-lactamase Inhibitors Product/Solution/Service
3.4 Date of Enter into Beta-lactam and Beta-lactamase Inhibitors Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Type (2014-2019)
4.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Application (2014-2019)

5 North America
5.1 North America Beta-lactam and Beta-lactamase Inhibitors Market Size (2014-2019)
5.2 Beta-lactam and Beta-lactamase Inhibitors Key Players in North America
5.3 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
5.4 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

6 Europe
6.1 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size (2014-2019)
6.2 Beta-lactam and Beta-lactamase Inhibitors Key Players in Europe
6.3 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
6.4 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

7 China
7.1 China Beta-lactam and Beta-lactamase Inhibitors Market Size (2014-2019)
7.2 Beta-lactam and Beta-lactamase Inhibitors Key Players in China
7.3 China Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
7.4 China Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

8 Japan
8.1 Japan Beta-lactam and Beta-lactamase Inhibitors Market Size (2014-2019)
8.2 Beta-lactam and Beta-lactamase Inhibitors Key Players in Japan
8.3 Japan Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
8.4 Japan Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Market Size (2014-2019)
9.2 Beta-lactam and Beta-lactamase Inhibitors Key Players in Southeast Asia
9.3 Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
9.4 Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

10 India
10.1 India Beta-lactam and Beta-lactamase Inhibitors Market Size (2014-2019)
10.2 Beta-lactam and Beta-lactamase Inhibitors Key Players in India
10.3 India Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
10.4 India Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

11 Central & South America
11.1 Central & South America Beta-lactam and Beta-lactamase Inhibitors Market Size (2014-2019)
11.2 Beta-lactam and Beta-lactamase Inhibitors Key Players in Central & South America
11.3 Central & South America Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
11.4 Central & South America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

12 International Players Profiles
12.1 Abbott Laboratories
12.1.1 Abbott Laboratories Company Details
12.1.2 Company Description and Business Overview
12.1.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
12.1.4 Abbott Laboratories Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019))
12.1.5 Abbott Laboratories Recent Development
12.2 Allergan Plc.
12.2.1 Allergan Plc. Company Details
12.2.2 Company Description and Business Overview
12.2.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
12.2.4 Allergan Plc. Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
12.2.5 Allergan Plc. Recent Development
12.3 F. Hoffmann-La Roche Ltd.
12.3.1 F. Hoffmann-La Roche Ltd. Company Details
12.3.2 Company Description and Business Overview
12.3.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
12.3.4 F. Hoffmann-La Roche Ltd. Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
12.3.5 F. Hoffmann-La Roche Ltd. Recent Development
12.4 GlaxoSmithKline plc
12.4.1 GlaxoSmithKline plc Company Details
12.4.2 Company Description and Business Overview
12.4.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
12.4.4 GlaxoSmithKline plc Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
12.4.5 GlaxoSmithKline plc Recent Development
12.5 Merck & Co. Inc.
12.5.1 Merck & Co. Inc. Company Details
12.5.2 Company Description and Business Overview
12.5.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
12.5.4 Merck & Co. Inc. Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
12.5.5 Merck & Co. Inc. Recent Development
12.6 Mylan N.V.
12.6.1 Mylan N.V. Company Details
12.6.2 Company Description and Business Overview
12.6.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
12.6.4 Mylan N.V. Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
12.6.5 Mylan N.V. Recent Development
12.7 Novartis International AG (Sandoz)
12.7.1 Novartis International AG (Sandoz) Company Details
12.7.2 Company Description and Business Overview
12.7.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
12.7.4 Novartis International AG (Sandoz) Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
12.7.5 Novartis International AG (Sandoz) Recent Development
12.8 Pfizer Inc.
12.8.1 Pfizer Inc. Company Details
12.8.2 Company Description and Business Overview
12.8.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
12.8.4 Pfizer Inc. Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
12.8.5 Pfizer Inc. Recent Development
12.9 Sanofi
12.9.1 Sanofi Company Details
12.9.2 Company Description and Business Overview
12.9.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
12.9.4 Sanofi Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
12.9.5 Sanofi Recent Development
12.10 Teva Pharmaceutical Industries Ltd
12.10.1 Teva Pharmaceutical Industries Ltd Company Details
12.10.2 Company Description and Business Overview
12.10.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
12.10.4 Teva Pharmaceutical Industries Ltd Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
12.10.5 Teva Pharmaceutical Industries Ltd Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Product (2019-2025)
13.2 Market Size Forecast by Application (2019-2025)
13.3 Market Size Forecast by Regions
13.4 North America
13.5 Europe
13.6 China
13.7 Japan
13.8 Southeast Asia
13.9 India
13.10 Central & South America

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details

List of Tables and Figures

Table Beta-lactam and Beta-lactamase Inhibitors Key Market Segments
Table Key Players Beta-lactam and Beta-lactamase Inhibitors Covered
Table Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate by Type 2018-2025 (Million US$)
Figuer Penicillin Figures
Table Key Players of Penicillin
Figuer Cephalosporin Figures
Table Key Players of Cephalosporin
Figuer Carbapenem Figures
Table Key Players of Carbapenem
Figuer Monobactam Figures
Table Key Players of Monobactam
Figuer Combination Figures
Table Key Players of Combination
Table Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth by Application 2019-2025 (Million US$)
Figure Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Application in 2018 & 2025
Figure Oral Case Studies
Figure Intravenous Case Studies
Figure Others Case Studies
Figure Beta-lactam and Beta-lactamase Inhibitors Report Years Considered
Figure Global Beta-lactam and Beta-lactamase Inhibitors Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Regions 2019-2025 (Million US$)
Table Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Regions 2019-2025 (Million US$)
Table Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Regions 2014-2019
Figure Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Regions 2014-2019
Figure Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Regions in 2018
Table Market Top Trends
Table Key Drivers: Impact Analysis (2019-2025)
Table Key Challenges
Figure PORTER'S FIVE FORCES ANALYSIS
Table Global Beta-lactam and Beta-lactamase Inhibitors Revenue by by Players (2014-2019) (Million US$)
Table Global Beta-lactam and Beta-lactamase Inhibitors Market Share by by Players (2014-2019)
Figure Global Beta-lactam and Beta-lactamase Inhibitors Market Share by by Players in 2018
Table Global Beta-lactam and Beta-lactamase Inhibitors by Players Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Beta-lactam and Beta-lactamase Inhibitors Product/Solution/Service
Table Date of Enter into Beta-lactam and Beta-lactamase Inhibitors Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Type (2014-2019) (Million US$)
Table Global Beta-lactam and Beta-lactamase Inhibitors Market Size Share by Type (2014-2019)
Figure Global Beta-lactam and Beta-lactamase Inhibitors Market Size Market Share by Type (2014-2019)
Table Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Application (2014-2019) (Million US$)
Table Global Beta-lactam and Beta-lactamase Inhibitors Market Size Share by Application (2014-2019)
Figure Global Beta-lactam and Beta-lactamase Inhibitors Market Size Market Share by Application (2014-2019)
Figure Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Application in 2018
Figure North America Beta-lactam and Beta-lactamase Inhibitors Market Size 2014-2019 (Million US$)
Table North America Key Players Beta-lactam and Beta-lactamase Inhibitors Revenue (2018-2019) (Million US$)
Table North America Key Players Beta-lactam and Beta-lactamase Inhibitors Market Share (2018-2019)
Table North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 2014-2019 (Million US$)
Table North America Beta-lactam and Beta-lactamase Inhibitors Market Share by Type 2014-2019
Table North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 2014-2019 (Million US$)
Table North America Beta-lactam and Beta-lactamase Inhibitors Market Share by Application 2014-2019
Figure Europe Beta-lactam and Beta-lactamase Inhibitors Market Size 2014-2019 (Million US$)
Table Europe Key Players Beta-lactam and Beta-lactamase Inhibitors Revenue (2018-2019) (Million US$)
Table Europe Key Players Beta-lactam and Beta-lactamase Inhibitors Market Share (2018-2019)
Table Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 2014-2019 (Million US$)
Table Europe Beta-lactam and Beta-lactamase Inhibitors Market Share by Type 2014-2019
Table Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 2014-2019 (Million US$)
Table Europe Beta-lactam and Beta-lactamase Inhibitors Market Share by Application 2014-2019
Figure China Beta-lactam and Beta-lactamase Inhibitors Market Size 2014-2019 (Million US$)
Table China Key Players Beta-lactam and Beta-lactamase Inhibitors Revenue (2018-2019) (Million US$)
Table China Key Players Beta-lactam and Beta-lactamase Inhibitors Market Share (2018-2019)
Table China Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 2014-2019 (Million US$)
Table China Beta-lactam and Beta-lactamase Inhibitors Market Share by Type 2014-2019
Table China Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 2014-2019 (Million US$)
Table China Beta-lactam and Beta-lactamase Inhibitors Market Share by Application 2014-2019
Figure Japan Beta-lactam and Beta-lactamase Inhibitors Market Size 2014-2019 (Million US$)
Table Japan Key Players Beta-lactam and Beta-lactamase Inhibitors Revenue (2018-2019) (Million US$)
Table Japan Key Players Beta-lactam and Beta-lactamase Inhibitors Market Share (2018-2019)
Table Japan Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 2014-2019 (Million US$)
Table Japan Beta-lactam and Beta-lactamase Inhibitors Market Share by Type 2014-2019
Table Japan Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 2014-2019 (Million US$)
Table Japan Beta-lactam and Beta-lactamase Inhibitors Market Share by Application 2014-2019
Figure Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Market Size 2014-2019 (Million US$)
Table Southeast Asia Key Players Beta-lactam and Beta-lactamase Inhibitors Revenue (2018-2019) (Million US$)
Table Southeast Asia Key Players Beta-lactam and Beta-lactamase Inhibitors Market Share (2018-2019)
Table Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 2014-2019 (Million US$)
Table Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Market Share by Type 2014-2019
Table Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 2014-2019 (Million US$)
Table Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Market Share by Application 2014-2019
Figure India Beta-lactam and Beta-lactamase Inhibitors Market Size 2014-2019 (Million US$)
Table India Key Players Beta-lactam and Beta-lactamase Inhibitors Revenue (2018-2019) (Million US$)
Table India Key Players Beta-lactam and Beta-lactamase Inhibitors Market Share (2018-2019)
Table India Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 2014-2019 (Million US$)
Table India Beta-lactam and Beta-lactamase Inhibitors Market Share by Type 2014-2019
Table India Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 2014-2019 (Million US$)
Table India Beta-lactam and Beta-lactamase Inhibitors Market Share by Application 2014-2019
Figure Central & South America Beta-lactam and Beta-lactamase Inhibitors Market Size 2014-2019 (Million US$)
Table Central & South America Key Players Beta-lactam and Beta-lactamase Inhibitors Revenue (2018-2019) (Million US$)
Table Central & South America Key Players Beta-lactam and Beta-lactamase Inhibitors Market Share (2018-2019)
Table Central & South America Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 2014-2019 (Million US$)
Table Central & South America Beta-lactam and Beta-lactamase Inhibitors Market Share by Type 2014-2019
Table Central & South America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 2014-2019 (Million US$)
Table Central & South America Beta-lactam and Beta-lactamase Inhibitors Market Share by Application 2014-2019
Table Abbott Laboratories Company Details
Table Abbott Laboratories Revenue in Beta-lactam and Beta-lactamase Inhibitors Business 2014-2019 (Million US$)
Figure Abbott Laboratories Revenue Growth Rate in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
Table Abbott Laboratories Recent Development
Table Allergan Plc. Company Details
Table Allergan Plc. Revenue in Beta-lactam and Beta-lactamase Inhibitors Business 2014-2019 (Million US$)
Figure Allergan Plc. Revenue Growth Rate in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
Table Allergan Plc. Recent Development
Table F. Hoffmann-La Roche Ltd. Company Details
Table F. Hoffmann-La Roche Ltd. Revenue in Beta-lactam and Beta-lactamase Inhibitors Business 2014-2019 (Million US$)
Figure F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
Table F. Hoffmann-La Roche Ltd. Recent Development
Table GlaxoSmithKline plc Company Details
Table GlaxoSmithKline plc Revenue in Beta-lactam and Beta-lactamase Inhibitors Business 2014-2019 (Million US$)
Figure GlaxoSmithKline plc Revenue Growth Rate in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
Table GlaxoSmithKline plc Recent Development
Table Merck & Co. Inc. Company Details
Table Merck & Co. Inc. Revenue in Beta-lactam and Beta-lactamase Inhibitors Business 2014-2019 (Million US$)
Figure Merck & Co. Inc. Revenue Growth Rate in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
Table Merck & Co. Inc. Recent Development
Table Mylan N.V. Company Details
Table Mylan N.V. Revenue in Beta-lactam and Beta-lactamase Inhibitors Business 2014-2019 (Million US$)
Figure Mylan N.V. Revenue Growth Rate in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
Table Mylan N.V. Recent Development
Table Novartis International AG (Sandoz) Company Details
Table Novartis International AG (Sandoz) Revenue in Beta-lactam and Beta-lactamase Inhibitors Business 2014-2019 (Million US$)
Figure Novartis International AG (Sandoz) Revenue Growth Rate in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
Table Novartis International AG (Sandoz) Recent Development
Table Pfizer Inc. Company Details
Table Pfizer Inc. Revenue in Beta-lactam and Beta-lactamase Inhibitors Business 2014-2019 (Million US$)
Figure Pfizer Inc. Revenue Growth Rate in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
Table Pfizer Inc. Recent Development
Table Sanofi Company Details
Table Sanofi Revenue in Beta-lactam and Beta-lactamase Inhibitors Business 2014-2019 (Million US$)
Figure Sanofi Revenue Growth Rate in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
Table Sanofi Recent Development
Table Teva Pharmaceutical Industries Ltd Company Details
Table Teva Pharmaceutical Industries Ltd Revenue in Beta-lactam and Beta-lactamase Inhibitors Business 2014-2019 (Million US$)
Figure Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
Table Teva Pharmaceutical Industries Ltd Recent Development
Table Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Regions (Million US$) 2019-2025
Figure Global Beta-lactam and Beta-lactamase Inhibitors Market Size Share by Regions (2019-2025)
Figure Global Beta-lactam and Beta-lactamase Inhibitors Market Size Share by Regions in 2025
Figure North America Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast (2019-2025)(Million USD)
Figure Europe Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast (2019-2025)(Million USD)
Figure China Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast (2019-2025)(Million USD)
Figure Japan Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast (2019-2025)(Million USD)
Figure Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast (2019-2025)(Million USD)
Figure India Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast (2019-2025)(Million USD)
Figure Central & South America Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast (2019-2025)(Million USD)
Table Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Product (2019-2025) (Million US$)
Figure Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Product (2019-2025)
Figure Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Product in 2025
Table Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Application (2019-2025) (Million US$)
Figure Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Application (2019-2025)
Figure Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources


【掲載企業】

Abbott Laboratories、Allergan Plc.、F. Hoffmann-La Roche Ltd.、GlaxoSmithKline plc、Merck & Co. Inc.、Mylan N.V.、Novartis International AG (Sandoz)、Pfizer Inc.、Sanofi、Teva Pharmaceutical Industries Ltd

★調査レポート[ベータラクタムおよびベータラクタマーゼ阻害剤の世界市場：規模・現状・予測2019-2025] (コード：DATA909X18221)販売に関する免責事項を必ずご確認ください。
★調査レポート[ベータラクタムおよびベータラクタマーゼ阻害剤の世界市場：規模・現状・予測2019-2025]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • ベータテストソフトウェアの世界市場：規模・現状・予測2019-2025
    DATA909X18220 / QYResearch / 2019年11月25日 / ※当調査レポートでは、ベータテストソフトウェアの世界市場について調査・分析し、ベータテストソフトウェアの世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（社内テスト、アウトソーシングテスト）、用途別（中小企業（中小企業）、大企業）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界のベータテストソフトウェア市場動向 ・主要企業別マーケットシェア ・ベータテストソフトウェアの種類別市場規模2014-2019 （社内テスト、アウトソーシングテスト） ・ベータテストソフトウェアの用途別市場規模2014-2019 （中小企業（中小企業）、大企業） ・ベータテストソフトウェアの北米市場：主要企業・種類別/用途別市場規模 ・ベータテストソフトウェアのヨーロッパ市場：主要企業・種類別/用途別市場規模...Beta testing is also sometimes referred to as user acceptance testing (UAT) or end user testing. In this phase of software development, applications are subjected to real world testing by the intended audience for the software. The experiences of the early users are forwarded back to the developers who make final changes before releasing the software commercially.In 2018, the global Beta Testing Software market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Beta Testing Software status, future...
  • B細胞リンパ腫2阻害剤の世界市場：規模・現状・予測2019-2025
    DATA909X18212 / QYResearch / 2019年11月25日 / ※当調査レポートでは、B細胞リンパ腫2阻害剤の世界市場について調査・分析し、B細胞リンパ腫2阻害剤の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（併用療法、単剤療法）、用途別（慢性リンパ性白血病、小リンパ球性リンパ腫、急性骨髄性白血病）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界のB細胞リンパ腫2阻害剤市場動向 ・主要企業別マーケットシェア ・B細胞リンパ腫2阻害剤の種類別市場規模2014-2019 （併用療法、単剤療法） ・B細胞リンパ腫2阻害剤の用途別市場規模2014-2019 （慢性リンパ性白血病、小リンパ球性リンパ腫、急性骨髄性白血病） ・B細胞リンパ腫2阻害剤の北米市場：主要企業・種類別/用途別市場規模 ・B細胞リンパ腫2阻害剤のヨーロッパ市場：主要企業・種類別/用途別市場規模...Bcl-2 (B-cell lymphoma 2), encoded in humans by the BCL2 gene, is the founding member of the Bcl-2 family of regulator proteins that regulate cell death (apoptosis), by either inhibiting (anti-apoptotic) or inducing (pro-apoptotic) apoptosis.The symptoms of hematological malignancies are often mild or not apparent, which delays diagnosis and treatment. To overcome this challenge, many organizations such as KNOW AML group and market vendors have been organizing awareness campaigns, which educate patients about the symptoms and available diagnostic methods and treatment options. This factor has increased the sales of various therapeutics, including BCL-2 inhibitors, which is a crucial drug for...
  • BCL-2（B細胞リンパ腫2）阻害剤の世界市場：規模・現状・予測2019-2025
    DATA909X18213 / QYResearch / 2019年11月25日 / ※当調査レポートでは、BCL-2（B細胞リンパ腫2）阻害剤の世界市場について調査・分析し、BCL-2（B細胞リンパ腫2）阻害剤の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（併用療法、単剤療法）、用途別（陽性リンパ腫、濾胞性リンパ腫、その他）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界のBCL-2（B細胞リンパ腫2）阻害剤市場動向 ・主要企業別マーケットシェア ・BCL-2（B細胞リンパ腫2）阻害剤の種類別市場規模2014-2019 （併用療法、単剤療法） ・BCL-2（B細胞リンパ腫2）阻害剤の用途別市場規模2014-2019 （陽性リンパ腫、濾胞性リンパ腫、その他） ・BCL-2（B細胞リンパ腫2）阻害剤の北米市場：主要企業・種類別/用途別市場規模 ・BCL-2（B細胞リンパ腫2）阻害剤のヨーロッパ市場：主要企業・種類別/用途別市場規模...Symptoms of hematologic malignancies are usually mild or inconspicuous, leading to delays in diagnosis and treatment of indications.BCL-2 (B-cell lymphoma 2) inhibitors  regulates the correlation of cell apoptosis at the mitochondrial level, which has the potential to be a therapeutic target for hematologic malignancies.In 2018, the global BCL-2 (B-cell lymphoma 2) Inhibitors market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global BCL-2 (B-cell lymphoma 2) Inhibitors status, future forecast, growth opportunity, key market and key players....
  • 選択的セロトニン再取り込み阻害薬（SSRI）の世界市場：規模・現状・予測2019-2025
    DATA909X18951 / QYResearch / 2019年11月25日 / ※当調査レポートでは、選択的セロトニン再取り込み阻害薬（SSRI）の世界市場について調査・分析し、選択的セロトニン再取り込み阻害薬（SSRI）の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（シタロプラム（セレキサ）、エシタロプラム（レキサプロ）、フルオキセチン（プロザック）、パロキセチン（パキシル、ペクセバ）、セルトラリン（ゾロフト）、ビラゾドン（ビブリド））、用途別（うつ病、不安およびパニック障害、その他の精神状態）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の選択的セロトニン再取り込み阻害薬（SSRI）市場動向 ・主要企業別マーケットシェア ・選択的セロトニン再取り込み阻害薬（SSRI）の種類別市場規模2014-2019 （シタロプラム（セレキサ）、エシタロプラム（レキサプロ）、フルオキセチン（プロザック）、パロキセチン（パキシル、ペクセバ）、セルトラリン（ゾロフト）、ビラゾドン（ビブリド）） ・選択的セロトニン再取り込み阻害薬（SSRI）の用途別市場規模2014-2019 （うつ病、不安およびパニック障害、その他の精神状態） ・選択的セロトニン再取り込み阻害薬（SSRI）の北米市場：主要企業・種類別/用途別市場規模 ・選択的セロトニン再取り込み阻害薬（SSRI）のヨーロッパ市場：主要企業・種類別/用途別市場規模...Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants. They can ease symptoms of moderate to severe depression, are relatively safe and typically cause fewer side effects than other types of antidepressants do.With an increase in mental illnesses, there is a rising need for effective neurological drugs. Among the various neurological drugs available in the market, SSRIs drugs have high therapeutic efficacy. As a result, the number of vendors manufacturing these drugs is increasing. Moreover, health insurance companies, with support from governments, have started covering treatment expenses related to mental disorder. The rising prevalence of mental illnesses will...
  • PARP（ポリADPリボースポリメラーゼ）阻害剤の世界市場：規模・現状・予測2019-2025
    DATA909X18797 / QYResearch / 2019年11月25日 / ※当調査レポートでは、PARP（ポリADPリボースポリメラーゼ）阻害剤の世界市場について調査・分析し、PARP（ポリADPリボースポリメラーゼ）阻害剤の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（オラパリブ、タラゾパリブ）、用途別（卵巣がん、乳がん、その他）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界のPARP（ポリADPリボースポリメラーゼ）阻害剤市場動向 ・主要企業別マーケットシェア ・PARP（ポリADPリボースポリメラーゼ）阻害剤の種類別市場規模2014-2019 （オラパリブ、タラゾパリブ） ・PARP（ポリADPリボースポリメラーゼ）阻害剤の用途別市場規模2014-2019 （卵巣がん、乳がん、その他） ・PARP（ポリADPリボースポリメラーゼ）阻害剤の北米市場：主要企業・種類別/用途別市場規模 ・PARP（ポリADPリボースポリメラーゼ）阻害剤のヨーロッパ市場：主要企業・種類別/用途別市場規模...PARP inhibitors are a group of pharmacological inhibitors of the enzyme polymerase ADP ribosome (PARP).They are developed for multiple indications.PARP inhibitors can enhance the efficacy of radiotherapy, alkalization agents and platinum-based chemotherapy by inhibiting DNA damage repair and promoting apoptosis of tumor cells. Parp (Poly Adp-Ribose Polymerase) inhibitors is very effective in treating solid tumors and other diseases.Such as advanced ovarian cancer, fallopian tube cancer and primary peritoneal cancer.In 2018, the global PARP (Poly ADP-ribose Polymerase) Inhibitors market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR...
  • 血管内皮増殖因子(VEGF)阻害剤の世界市場：規模・現状・予測2019-2025
    DATA909X19071 / QYResearch / 2019年11月25日 / ※当調査レポートでは、血管内皮増殖因子(VEGF)阻害剤の世界市場について調査・分析し、血管内皮増殖因子(VEGF)阻害剤の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（VEGF-A阻害剤、VEGF-B阻害剤、VEGF-C阻害剤、VEGF-D阻害剤）、用途別（腫瘍学、眼科）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の血管内皮増殖因子(VEGF)阻害剤市場動向 ・主要企業別マーケットシェア ・血管内皮増殖因子(VEGF)阻害剤の種類別市場規模2014-2019 （VEGF-A阻害剤、VEGF-B阻害剤、VEGF-C阻害剤、VEGF-D阻害剤） ・血管内皮増殖因子(VEGF)阻害剤の用途別市場規模2014-2019 （腫瘍学、眼科） ・血管内皮増殖因子(VEGF)阻害剤の北米市場：主要企業・種類別/用途別市場規模 ・血管内皮増殖因子(VEGF)阻害剤のヨーロッパ市場：主要企業・種類別/用途別市場規模...Vascular endothelial growth factor inhibitors, also known as angiogenesis inhibitors, can prevent the generation of new blood vessels. The vascular endothelial growth factor is a protein that can trigger endothelial cells or pre-existing vessels to form new blood vessels. However, overexpression of vascular endothelial growth factor can generate cancerous cells. In 2018, the global Vascular Endothelial Growth Factor (VEGF) Inhibitors market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Vascular Endothelial Growth Factor (VEGF) Inhibitors status,...

    • ◆H&Iグローバルリサーチのお客様（例）◆